Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Income Statement
Earnings Waterfall
Centessa Pharmaceuticals PLC
Income Statement
Centessa Pharmaceuticals PLC
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
5
|
7
|
10
|
10
|
10
|
10
|
10
|
10
|
11
|
11
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
7
N/A
|
7
N/A
|
7
N/A
|
7
N/A
|
0
N/A
|
15
N/A
|
15
N/A
|
15
N/A
|
|
| Operating Income | |||||||||||||||||||||
| Operating Expenses |
(10)
|
(26)
|
(62)
|
(319)
|
(154)
|
(188)
|
(218)
|
(229)
|
(212)
|
(208)
|
(187)
|
(178)
|
(178)
|
(165)
|
(162)
|
(168)
|
(201)
|
(244)
|
(255)
|
(263)
|
|
| Selling, General & Administrative |
(1)
|
(9)
|
(18)
|
(30)
|
(43)
|
(49)
|
(55)
|
(54)
|
(55)
|
(57)
|
(55)
|
(55)
|
(54)
|
(51)
|
(49)
|
(50)
|
(51)
|
(50)
|
(51)
|
(50)
|
|
| Research & Development |
(9)
|
(17)
|
(33)
|
(57)
|
(96)
|
(122)
|
(158)
|
(169)
|
(155)
|
(151)
|
(131)
|
(123)
|
(124)
|
(114)
|
(113)
|
(119)
|
(150)
|
(161)
|
(171)
|
(179)
|
|
| Other Operating Expenses |
0
|
0
|
(11)
|
(232)
|
(15)
|
(17)
|
(6)
|
(6)
|
(2)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(33)
|
(33)
|
(34)
|
|
| Operating Income |
(10)
N/A
|
(26)
-151%
|
(62)
-137%
|
(319)
-413%
|
(154)
+52%
|
(188)
-22%
|
(218)
-16%
|
(229)
-5%
|
(212)
+7%
|
(208)
+2%
|
(187)
+10%
|
(178)
+5%
|
(171)
+4%
|
(158)
+7%
|
(155)
+2%
|
(161)
-4%
|
(201)
-25%
|
(229)
-14%
|
(240)
-5%
|
(248)
-3%
|
|
| Pre-Tax Income | |||||||||||||||||||||
| Interest Income Expense |
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(3)
|
(4)
|
(6)
|
(7)
|
(5)
|
(4)
|
(2)
|
1
|
0
|
2
|
2
|
4
|
9
|
10
|
10
|
|
| Non-Reccuring Items |
0
|
(220)
|
(220)
|
0
|
(220)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(34)
|
0
|
0
|
0
|
|
| Total Other Income |
(0)
|
(0)
|
(3)
|
(5)
|
(6)
|
(5)
|
3
|
1
|
2
|
1
|
(6)
|
(5)
|
(5)
|
(6)
|
(4)
|
1
|
(2)
|
1
|
4
|
(1)
|
|
| Pre-Tax Income |
(11)
N/A
|
(247)
-2 218%
|
(286)
-16%
|
(324)
-13%
|
(381)
-18%
|
(196)
+49%
|
(220)
-12%
|
(234)
-6%
|
(217)
+7%
|
(213)
+2%
|
(197)
+7%
|
(184)
+6%
|
(176)
+4%
|
(164)
+7%
|
(158)
+4%
|
(158)
0%
|
(233)
-47%
|
(220)
+6%
|
(227)
-3%
|
(239)
-6%
|
|
| Net Income | |||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
1
|
0
|
24
|
27
|
25
|
25
|
0
|
(3)
|
(3)
|
(4)
|
(4)
|
(3)
|
|
| Income from Continuing Operations |
(11)
|
(247)
|
(286)
|
(324)
|
(381)
|
(196)
|
(220)
|
(234)
|
(216)
|
(212)
|
(173)
|
(157)
|
(151)
|
(138)
|
(158)
|
(162)
|
(236)
|
(224)
|
(231)
|
(243)
|
|
| Net Income (Common) |
(11)
N/A
|
(247)
-2 218%
|
(286)
-16%
|
(324)
-13%
|
(381)
-18%
|
(196)
+49%
|
(220)
-12%
|
(234)
-6%
|
(216)
+8%
|
(212)
+2%
|
(173)
+19%
|
(157)
+9%
|
(151)
+4%
|
(138)
+8%
|
(158)
-14%
|
(162)
-3%
|
(236)
-46%
|
(224)
+5%
|
(231)
-3%
|
(243)
-5%
|
|
| EPS (Diluted) |
-0.12
N/A
|
-2.83
-2 258%
|
-3.91
-38%
|
-3.59
+8%
|
-5.07
-41%
|
-2.16
+57%
|
-2.33
-8%
|
-2.47
-6%
|
-2.31
+6%
|
-2.25
+3%
|
-1.82
+19%
|
-1.62
+11%
|
-1.57
+3%
|
-1.38
+12%
|
-1.44
-4%
|
-1.39
+3%
|
-2.06
-48%
|
-1.68
+18%
|
-1.72
-2%
|
-1.82
-6%
|
|